BriaCell Therapeutics Corp. (TSX:BCT)
Canada · Delayed Price · Currency is CAD 5.40
-0.17 (-3.05%)
Nov 9, 2026, 1:00 PM EST
BriaCell Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is August - July.
Millions USD. Fiscal year is Aug - Jul.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Cash & Equivalents | 9.85 | 10.49 | 0.86 | 21.25 | 41.04 |
Short-Term Investments | 10.69 | 7.37 | - | - | - |
Cash & Short-Term Investments | 20.54 | 17.87 | 0.86 | 21.25 | 41.04 |
Cash Growth | 14.97% | 1972.44% | -95.94% | -48.22% | -28.34% |
Other Receivables | 1.5 | - | 0.74 | - | 0.02 |
Receivables | 1.5 | - | 0.74 | - | 0.02 |
Prepaid Expenses | - | 2.06 | 2.06 | 5.7 | 1.28 |
Total Current Assets | 22.04 | 19.93 | 3.65 | 26.95 | 42.35 |
Property, Plant & Equipment | 0.32 | 0.3 | 0.39 | - | - |
Long-Term Investments | 0.73 | 0.52 | 0.42 | 0 | 0 |
Other Intangible Assets | 0.17 | 0.18 | 0.2 | 0.22 | 0.23 |
Other Long-Term Assets | 0.32 | 0.72 | 1.21 | - | - |
Total Assets | 23.58 | 21.65 | 5.87 | 27.16 | 42.58 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Accounts Payable | 6.99 | 3.28 | 7.17 | 1.12 | 0.46 |
Accrued Expenses | 0.99 | 0.69 | 0.29 | 0.68 | 0.48 |
Total Current Liabilities | 7.98 | 3.98 | 7.46 | 1.8 | 0.94 |
Other Long-Term Liabilities | 0.04 | 0.34 | 1.1 | 29.14 | 31.31 |
Total Liabilities | 8.02 | 4.32 | 8.56 | 30.94 | 32.25 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Common Stock | 120.91 | 101.74 | 72.17 | 69.59 | 65.59 |
Retained Earnings | -146.66 | -111.76 | -85.44 | -80.65 | -60.35 |
Comprehensive Income & Other | 42.15 | 27.9 | 10.89 | 7.28 | 5.09 |
Total Common Equity | 16.4 | 17.88 | -2.38 | -3.78 | 10.33 |
Minority Interest | -0.84 | -0.55 | -0.3 | - | - |
Shareholders' Equity | 15.56 | 17.33 | -2.68 | -3.78 | 10.33 |
Total Liabilities & Equity | 23.58 | 21.65 | 5.87 | 27.16 | 42.58 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Jul '25 Jul 31, 2025 | Jul '24 Jul 31, 2024 | Jul '23 Jul 31, 2023 | Jul '22 Jul 31, 2022 |
Net Cash (Debt) | 20.54 | 17.87 | 0.86 | 21.25 | 41.04 |
Net Cash Growth | 14.97% | 1972.44% | -95.94% | -48.22% | -28.30% |
Net Cash Per Share | 4.10 | 42.23 | 7.86 | 204.08 | 397.33 |
Filing Date Shares Outstanding | 8.73 | 1.88 | 0.12 | 0.11 | 0.1 |
Total Common Shares Outstanding | 8.71 | 1.88 | 0.12 | 0.11 | 0.1 |
Working Capital | 14.06 | 15.95 | -3.81 | 25.15 | 41.41 |
Book Value Per Share | 1.88 | 9.49 | -19.54 | -35.45 | 99.84 |
Tangible Book Value | 16.23 | 17.7 | -2.58 | -3.99 | 10.1 |
Tangible Book Value Per Share | 1.86 | 9.39 | -21.18 | -37.47 | 97.61 |
Machinery | - | 0.46 | 0.46 | - | - |